Chronic demyelinating polyradiculoneuropathy (CIDP) is an acquired, potentially crippling sensorymotor polyneuropathy of variable course. 1 It is likely autoimmune because sural nerve histopathology reveals infiltrating CD68ϩ macrophages, endoneurial and epineurial CD3ϩ T cells with immunoglobulin G, immunoglobulin M, and complement deposits on myelin sheaths. 1 Macrophages penetrate the basal lamina of Schwann cells and split myelin lamellae, a process referred to as "macrophage-mediated demyelination." Nerve injury ensues due to a combination of antibody-, complement-, and macrophagedependent demyelination. The majority of patients therefore respond to corticosteroids, plasmapheresis, or IV immunoglobulin (IVIg). The Immune Globulin IV CIDP Efficacy (ICE) study, the largest therapeutic trial in CIDP, convincingly demonstrated short-and long-term benefits of IVIg treatment. 2 Response to plasmapheresis or IVIg is consistent with humoral and Fc receptor-mediated cellular effector mechanisms.
In this issue of Neurology ® , Schneider-Hohendorf et al. 3 present evidence that CD8ϩ cytotoxic T cells contribute to the pathogenesis of CIDP: nerveinfiltrating CD8ϩ T cells are clonally expanded, with expanded T-cell clones also detectable in blood. In one especially informative patient, expanded T-cell receptor (TCR) ␤-chain variable (TCRV␤) 5.1ϩ T cells were enriched in sural nerve compared to blood. To interpret and understand these results, one needs to consider the methodology used in the study. CD8ϩ (cytotoxic) T cells typically recognize a short peptide composed of 8 -10 amino acids bound to a human leukocyte antigen (HLA) class 1 molecule displayed on the surface of a target cell. The HLA-bound peptide is recognized by the hypervariable, complementarity determining region (CDR) of the antigen-specific TCR on the cytotoxic T cell. TCRs are clonally distributed: about 10 15 different TCRs are theoretically possible, and about 3 ϫ 10 7 to 10 9 distinct T-cell clones are present in the human immune system, each carrying one type of unique TCR. 4 In contrast to B-cell receptors, which are also clonally distributed, TCRs do not undergo affinity maturation by somatic hypermutation, so that the post-thymic TCR repertoire is essentially fixed. Therefore, analysis of the clonal composition of tissue-infiltrating T cells and of their TCR repertoire indicates their distribution and antigen recognition properties, and therefore, their pathogenic relevance. This is the basis for the greatly popular "TCR repertoire studies" by clinical immunologists.
To prove T cells are pathogenic, there should be morphologic evidence of CD8ϩ T-cell-mediated tissue injury. The mere presence of CD8ϩ cells provides only tentative evidence, but direct contact between T cells and HLA class 1-expressing target cells is strong evidence for a CD8ϩ T-cell-mediated attack. For example, in muscle of patients with inclusion body myositis, non-necrotic, HLA class 1-expressing muscle fibers are surrounded and invaded by activated CD8ϩ T cells, 5 which release their cytotoxic granules toward the attacked fiber. 6 Such a "kiss of death" between a cytotoxic T cell and a target cell (neuron or astrocyte) also occurs in Rasmussen encephalitis. 7 The morphologic evidence in the CIDP article is indirect, because only the presence of CD8ϩ T cells was demonstrated. 3 A second line of evidence is clonal expansion or clonal dominance of the incriminated T cells, demonstrated by immunostaining with monoclonal antibodies directed against 24 human TCR variable ␤-chain (V␤) families. In the CIDP study, this was achieved in one patient by using an anti-TCR V␤5.1 monoclonal antibody. Furthermore, molecular evidence for clonal expansion may be obtained by "TCR-CDR3 spectratyping." 8 This method makes use of the "junctional diversity" generated when TCRs are created by somatic recombination of TCR-encoding gene segments. This occurs in the thymus and results in varieties of the CDR3 regions of the TCR V␤ chains. Using oligonucleotide primers for 24 human V␤ gene families, the CDR3 length distribution can be analyzed for each TCR V␤ family. A significant devi-ation from the usual distribution in the transcripts of any TCR V␤ family is evidence for clonal expansion of the corresponding T cells in the inflammatory infiltrate and is, therefore, evidence of pathogenic importance. In the CIDP study, 3 CDR3 spectratyping revealed strong clonal expansions in sural nerve biopsy specimens. The same expansions could be observed in CD8ϩ T cells from patients' peripheral blood. Clonal identity was confirmed by sequence comparison of the TCR CDR3 regions. 3 Apart from clonal expansion, TCR repertoire analysis may provide additional clues to pathogenic relevance. One such feature is "pervasiveness": the pathogenic role of an expanded T-cell clone is corroborated if it is present at different sites in the affected tissue, or in other tissues (e.g., blood or CSF). Similarly, temporal persistence of expanded T-cell clones would argue for their pathogenic relevance. Finally, silent nucleotide exchanges in the TCR CDR3 regions point to pathogenic relevance. These additional features were detected, for example, in MS, 9 but have not yet been demonstrated in CIDP (table) .
The new study 3 provides startling, yet preliminary evidence for a pathogenic role of CD8ϩ in CIDP. Even if future investigations showed that the nerveinfiltrating CD8ϩ T cells do not act directly as cytotoxic effector cells, they might still play a role by recognizing a target antigen involved in the immunopathogenesis of CIDP. This might be an autoantigen or, perhaps, viral antigen. How could one proceed to further analyze the nerve-infiltrating T cells? One approach would be to "resurrect" the T cells from nerve specimens, and to use the resurrected cells for identifying their target antigens. This task is far from trivial, but owing to a new method, it would be technically feasible. 10 Abbreviations: CIDP ϭ chronic inflammatory demyelinating polyradiculoneuropathy; IBM ϭ inclusion body myositis; MS ϭ multiple sclerosis; PM ϭ polymyositis; TCR ϭ T-cell receptor.
AUTHOR CONTRIBUTIONS

